China’s Impact Therapeutics raises at most $910 million in Hong Kong IPO

China’s Impact Therapeutics is seeking to raise at most HK$910 million in its Hong Kong initial public offering.

The commercial-stage biotechnology company focused on cancer treatment plans to offer 41.98 million H shares at an offer price of HK$19.75 to HK$21.75 per share. The entry fee for each board lot of 200 shares is HK$4,393.9.

It is scheduled to debut on May 13.
 

 

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗧𝗵𝗲 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗔𝗽𝗽 ↓